PMID- 16849627 OWN - NLM STAT- MEDLINE DCOM- 20061212 LR - 20220317 IS - 0193-1849 (Print) IS - 0193-1849 (Linking) VI - 291 IP - 6 DP - 2006 Dec TI - Inhibition of human IAPP fibril formation does not prevent beta-cell death: evidence for distinct actions of oligomers and fibrils of human IAPP. PG - E1317-24 AB - Type 2 diabetes mellitus (T2DM) is characterized by an approximately 60% deficit in beta-cell mass, increased beta-cell apoptosis, and islet amyloid derived from islet amyloid polypeptide (IAPP). Human IAPP (hIAPP) forms oligomers, leading to either amyloid fibrils or toxic oligomers in an aqueous solution in vitro. Either application of hIAPP on or overexpression of hIAPP in cells induces apoptosis. It remains controversial whether the fibrils or smaller toxic oligomers induce beta-cell apoptosis. Rifampicin prevents hIAPP amyloid fibril formation and has been proposed as a potential target for prevention of T2DM. We examined the actions of rifampicin on hIAPP amyloid fibril and toxic oligomer formation as well as its ability to protect beta-cells from either application of hIAPP or endogenous overexpression of hIAPP (transgenic rats and adenovirus-transduced beta-cells). We report that rifampicin (Acocella G. Clin Pharmacokinet 3: 108-127, 1978) prevents hIAPP fibril formation, but not formation of toxic hIAPP oligomers (Bates G. Lancet 361: 1642-1644, 2003), and does not protect beta-cells from apoptosis induced by either overexpression or application of hIAPP. These data emphasize that toxic hIAPP oligomers, rather than hIAPP fibrils, initiate beta-cell apoptosis and that screening tools to identify inhibitors of amyloid fibril formation are likely to be less useful than those that identify inhibitors of toxic oligomer formation. Finally, rifampicin and related molecules do not appear to be useful as candidates for prevention of T2DM. FAU - Meier, Juris J AU - Meier JJ AD - Larry Hillblom Islet Research Center, University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA 90095-7073, USA. FAU - Kayed, Rakez AU - Kayed R FAU - Lin, Chia-Yu AU - Lin CY FAU - Gurlo, Tatyana AU - Gurlo T FAU - Haataja, Leena AU - Haataja L FAU - Jayasinghe, Sajith AU - Jayasinghe S FAU - Langen, Ralf AU - Langen R FAU - Glabe, Charles G AU - Glabe CG FAU - Butler, Peter C AU - Butler PC LA - eng GR - DK-59579/DK/NIDDK NIH HHS/United States GR - NS-31230/NS/NINDS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20060718 PL - United States TA - Am J Physiol Endocrinol Metab JT - American journal of physiology. Endocrinology and metabolism JID - 100901226 RN - 0 (Amyloid beta-Protein Precursor) RN - 0 (Benzothiazoles) RN - 0 (Coloring Agents) RN - 0 (DNA, Complementary) RN - 0 (Fluorescent Dyes) RN - 0 (Tetrazolium Salts) RN - 0 (Thiazoles) RN - 2390-54-7 (thioflavin T) RN - 36015-30-2 (Propidium) RN - EUY85H477I (thiazolyl blue) RN - VJT6J7R4TR (Rifampin) SB - IM MH - Adenoviridae/genetics MH - Amyloid beta-Protein Precursor/*chemistry/*physiology MH - Animals MH - Apoptosis/physiology MH - Benzothiazoles MH - Blotting, Western MH - Cell Death/physiology MH - Coloring Agents MH - DNA, Complementary/biosynthesis/genetics MH - Fluorescent Dyes MH - Humans MH - In Situ Nick-End Labeling MH - Insulin-Secreting Cells/*physiology MH - Islets of Langerhans/*chemistry/*physiology MH - Propidium MH - Rats MH - Rats, Sprague-Dawley MH - Rifampin/pharmacology MH - Tetrazolium Salts MH - Thiazoles EDAT- 2006/07/20 09:00 MHDA- 2006/12/13 09:00 CRDT- 2006/07/20 09:00 PHST- 2006/07/20 09:00 [pubmed] PHST- 2006/12/13 09:00 [medline] PHST- 2006/07/20 09:00 [entrez] AID - 00082.2006 [pii] AID - 10.1152/ajpendo.00082.2006 [doi] PST - ppublish SO - Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1317-24. doi: 10.1152/ajpendo.00082.2006. Epub 2006 Jul 18.